Word

TIGEN

Status

Pending

Status Code

774

Status Date

Monday, March 28, 2022

Serial Number

79311144

Mark Type

5000

Filing Date

Thursday, February 4, 2021

Published for Opposition

Tuesday, February 15, 2022

Trademark Owner History

Tigen Pharma SA - Owner At Publication

Classifications

5 Pharmaceutical products and medical preparations, namely, gene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseases, genetic diseases, autoimmune diseases and infectious diseases

1 Chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in industry and science; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in the development being the manufacture, and manufacture of reagents for industrial or scientific use; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides or proteins, for use of laboratories, diagnostics and analyses for industrial or scientific use; chemical, biochemical, biological and biotechnological substances, namely, polypeptides and proteins, for use in the manufacture of pharmaceuticals

44 Medical services; pharmacy advice services, namely, pharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists

10 Medical instruments, equipment and apparatus, namely, instruments, equipment and apparatus for cell and cell material collection, thawing, washing, selection, expansion, modification, harvesting, final formulation, freezing, storage and infusion into a patient in the fields of genetic diseases, autoimmune diseases, infectious diseases, localized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions

42 Scientific research, technological development of new products for third parties; medical research; scientific and industrial research in biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific services, namely, development of medicines, active substances and vaccines; scientific services, namely, development of food supplement; design and development of computer hardware and software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; upgrading, maintenance and rental of computer software; updating, maintenance and rental of computer software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process development, manufacturing, quality, and supply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; chemical and biological laboratory services

Trademark Events

Dec 31, 2023

New Representative At Ib Received

Dec 11, 2023

Notification Of Possible Opposition - Processed By Ib

Nov 8, 2023

Notification Of Possible Opposition Sent To Ib

Nov 8, 2023

Notification Of Possible Opposition Created, To Be Sent To Ib

Aug 2, 2022

Correction From The Ib Examined, No Action Is Needed

Jun 5, 2022

Correction Transaction Received From Ib

Apr 10, 2022

Refusal Processed By Ib

Mar 28, 2022

Opposition Instituted No. 999999

Mar 16, 2022

Opposition Notice (Ib Refusal) Sent To Ib

Mar 16, 2022

Opposition Notice (Ib Refusal) Created

Mar 15, 2022

Opposition Papers Received At Ttab

Feb 15, 2022

Official Gazette Publication Confirmation E-Mailed

Feb 15, 2022

Published For Opposition

Feb 14, 2022

Notification Processed By Ib

Jan 26, 2022

Notification Of Possible Opposition Sent To Ib

Jan 26, 2022

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jan 26, 2022

Notification Of Notice Of Publication E-Mailed

Jan 11, 2022

Law Office Publication Review Completed

Jan 11, 2022

Assigned To Lie

Jan 10, 2022

Approved For Pub - Principal Register

Jan 10, 2022

Examiner's Amendment Entered

Jan 10, 2022

Notification Of Examiners Amendment E-Mailed

Jan 10, 2022

Examiners Amendment E-Mailed

Jan 10, 2022

Examiners Amendment -Written

Jan 7, 2022

Applicant/Correspondence Changes (Non-Responsive) Entered

Jan 7, 2022

Teas Change Of Correspondence Received

Jan 7, 2022

Teas Change Of Domestic Representatives Address

Jan 7, 2022

Attorney/Dom.Rep.Revoked And/Or Appointed

Jan 7, 2022

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Jan 7, 2022

Teas Change Of Owner Address Received

Oct 4, 2021

Refusal Processed By Ib

Sep 14, 2021

Non-Final Action Mailed - Refusal Sent To Ib

Sep 14, 2021

Refusal Processed By Mpu

Sep 14, 2021

Non-Final Action (Ib Refusal) Prepared For Review

Sep 13, 2021

Non-Final Action Written

Aug 27, 2021

Assigned To Examiner

Aug 20, 2021

New Representative At Ib Received

May 25, 2021

Application Filing Receipt Mailed

May 21, 2021

New Application Office Supplied Data Entered

May 20, 2021

Sn Assigned For Sect 66a Appl From Ib